Lay A TRAP for myeloid cell response in diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Immunology

Background:

• The renin-angiotensin system plays a critical role in diabetic kidney disease progression.
• Angiotensin II receptor-associated protein (ATRAP) is a negative regulator of angiotensin II signaling.
• Understanding ATRAP's function is key to developing new therapeutic strategies for diabetic kidney disease.

Purpose of the Study:

• To investigate the role of ATRAP in diabetic kidney disease.
• To explore the impact of ATRAP deficiency on kidney inflammation and injury.
• To elucidate the crosstalk between glomerular injury, tubulointerstitial signaling, and innate immunity.

Main Methods:

• Utilized a mouse model of diabetic kidney disease with ATRAP deficiency.
• Employed adoptive transfer of ATRAP-expressing cells.
• Performed tubule-specific depletion of ATRAP.
• Assessed macrophage infiltration and albuminuria levels.

Main Results:

• ATRAP deficiency in diabetic mice led to decreased anti-inflammatory macrophage infiltration.
• ATRAP deficiency exacerbated albuminuria, indicating worsened kidney damage.
• Adoptive transfer and tubule-specific depletion studies revealed crosstalk between glomerular injury and tubulointerstitial signaling.

Conclusions:

• ATRAP deficiency impairs anti-inflammatory responses in diabetic kidney disease.
• ATRAP plays a significant role in modulating innate immunity and angiotensin II signaling in the kidneys.
• Targeting ATRAP may offer a novel therapeutic approach for managing diabetic kidney disease.